Concentrix Earnings Calls
| Release date | Jun 29, 2026 |
| EPS estimate | $2.64 |
| EPS actual | $2.63 |
| EPS Surprise | -0.379% |
| Revenue estimate | 2.473B |
| Revenue actual | 2.462B |
| Revenue Surprise | -0.430% |
| Release date | Mar 24, 2026 |
| EPS estimate | $2.64 |
| EPS actual | $2.61 |
| EPS Surprise | -1.14% |
| Revenue estimate | 2.493B |
| Revenue actual | 2.5B |
| Revenue Surprise | 0.312% |
| Release date | Jan 13, 2026 |
| EPS estimate | $2.91 |
| EPS actual | $2.95 |
| EPS Surprise | 1.37% |
| Revenue estimate | 2.54B |
| Revenue actual | 2.553B |
| Revenue Surprise | 0.524% |
| Release date | Sep 25, 2025 |
| EPS estimate | $2.88 |
| EPS actual | $2.78 |
| EPS Surprise | -3.47% |
| Revenue estimate | 2.46B |
| Revenue actual | 2.483B |
| Revenue Surprise | 0.95% |
Last 4 Quarters for Concentrix
Below you can see how CNXC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Sep 25, 2025 |
| Price on release | $54.99 |
| EPS estimate | $2.88 |
| EPS actual | $2.78 |
| EPS surprise | -3.47% |
| Date | Price |
|---|---|
| Sep 19, 2025 | $56.97 |
| Sep 22, 2025 | $55.53 |
| Sep 23, 2025 | $55.09 |
| Sep 24, 2025 | $55.60 |
| Sep 25, 2025 | $54.99 |
| Sep 26, 2025 | $47.66 |
| Sep 29, 2025 | $47.83 |
| Sep 30, 2025 | $46.15 |
| Oct 01, 2025 | $48.22 |
| 4 days before | -3.48% |
| 4 days after | -12.31% |
| On release day | -13.33% |
| Change in period | -15.36% |
| Release date | Jan 13, 2026 |
| Price on release | $39.18 |
| EPS estimate | $2.91 |
| EPS actual | $2.95 |
| EPS surprise | 1.37% |
| Date | Price |
|---|---|
| Jan 07, 2026 | $42.89 |
| Jan 08, 2026 | $44.07 |
| Jan 09, 2026 | $44.06 |
| Jan 12, 2026 | $40.48 |
| Jan 13, 2026 | $39.18 |
| Jan 14, 2026 | $41.42 |
| Jan 15, 2026 | $42.18 |
| Jan 16, 2026 | $43.15 |
| Jan 20, 2026 | $40.11 |
| 4 days before | -8.65% |
| 4 days after | 2.37% |
| On release day | 5.72% |
| Change in period | -6.48% |
| Release date | Mar 24, 2026 |
| Price on release | $26.48 |
| EPS estimate | $2.64 |
| EPS actual | $2.61 |
| EPS surprise | -1.14% |
| Date | Price |
|---|---|
| Mar 18, 2026 | $30.78 |
| Mar 19, 2026 | $31.92 |
| Mar 20, 2026 | $31.52 |
| Mar 23, 2026 | $33.04 |
| Mar 24, 2026 | $26.48 |
| Mar 25, 2026 | $24.67 |
| Mar 26, 2026 | $27.72 |
| Mar 27, 2026 | $26.42 |
| Mar 30, 2026 | $26.68 |
| 4 days before | -13.97% |
| 4 days after | 0.755% |
| On release day | -6.84% |
| Change in period | -13.32% |
| Release date | Jun 29, 2026 |
| Price on release | $25.23 |
| EPS estimate | $2.64 |
| EPS actual | $2.63 |
| EPS surprise | -0.379% |
| Date | Price |
|---|---|
| Jun 23, 2026 | $24.34 |
| Jun 24, 2026 | $24.24 |
| Jun 25, 2026 | $22.52 |
| Jun 26, 2026 | $25.00 |
| Jun 29, 2026 | $25.23 |
| Jun 30, 2026 | $22.41 |
| Jul 01, 2026 | $24.41 |
| Jul 02, 2026 | $23.60 |
| Jul 06, 2026 | $23.42 |
| 4 days before | 3.66% |
| 4 days after | -7.17% |
| On release day | -11.20% |
| Change in period | -3.78% |
Concentrix Earnings Call Transcript Summary of Q2 2026
Concentrix reported accelerating momentum in technology-led services, driven by strong IX Suite adoption and AI-enabled offerings. Key operational highlights: IX Suite deals surged (closed ~100 deals in Q2), technology-with-service deal counts rose (25% YoY) and AI-with-service deals rose 80% YoY; 11% of revenue is now influenced by IX Suite deployments and the company expects to double IX Suite revenue toward ~$120M ARR by year-end. Management emphasized that 97% of their top 75% of clients have AI in production, creating more complex environments and cross‑sell opportunities. Financials: Q2 adjusted free cash flow was a record $242M; non-GAAP operating margin was 11.9% and adjusted EBITDA margin 14.1%, both up modestly sequentially. Guidance: Q3 revenue $2.465–2.490B (0–1% constant currency growth) and FY26 revenue $9.925–10.025B (0.25–1.25% CC growth) with FY non‑GAAP operating income $1.2–1.23B (12.1–12.3% margin). Management now expects an extra headwind from accelerated offshoring (now ~3% vs prior ~2%) plus ~1% from client reprioritizations. Capital allocation and balance sheet: Adjusted FCF guide $630–650M for FY26; planned debt repayments >$550M in 2026 to reduce net debt to ~ $3.8B and a target net leverage below 2.0x adjusted EBITDA by year-end 2026. Restructuring and efficiency: the company is accelerating offshoring and automation, expects ~$175M of restructuring spend this year (including an additional ~$75M called out earlier), and expects the cash cost to be recouped within 6–9 months on a cash basis. Management reiterated focus on (1) scaling IX Suite deployments faster, (2) investing in AI/product and deployment talent, (3) margin expansion in H2, and (4) aggressive debt reduction using strong free cash flow.
Sign In
Buy CNXC